Many arrhythmias have no clear cause; these idiopathic cases arise without identifiable triggers, while for others, the ...
Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results